Kit ELISA MBL sandwich(MBL2) (human): quantitative determination of Hu MBL in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu MBL.
Accession number
P11226
Dose range
0.034-25 ng/ml
Sensitivity of the dosage
0.03 ng
Calibration range
0.03 ng/ml to 25 ng/ml
Dose
ELISA solid-phase sandwich
Brand
Invitrogen
Kit ELISA MBL sandwich(MBL2) (human): quantitative determination of Hu MBL in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu MBL.
Kit ELISA MBL sandwich(MBL2) (human): quantitative determination of Hu MBL in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu MBL.
Method principle: This ELISA solid phase sandwich test (immuno-enzymatic dose) measures the amount of target bound between a pair of matched antibodies. A specific target antibody is pre-adsorbed into the wells of the supplied microplate. Samples, standards or controls are added to these wells and bind to immobilized antibodies (capture antibodies). The sandwich is formed by adding the second antibody (detection antibody), then a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of the target present in the original sample.
Rigorous validation: Each batch manufactured from this ELISA kit is checked for criteria such as sensitivity, specificity, accuracy and reproducibility from one batch to another (see the package leaflet for more information on validation).
Lectine binding mannan (MBL; also called lectine or mannose binding protein) is a protein binding the multimeric carbohydrates produced in the liver and secreted in the blood, where it is an important element in the innate immune defense against invasive microorganisms. Its normally oligomerized forms are associated with specific serial proproteinases (MASP) that are activated when MBL binds to microbial surfaces of carbohydrates and, in turn, activates the supplement via the MBL or lectin route. Determination of serum concentrations of MBL may be useful for elucidating suspected immune defects and as a prognostic indicator warning the need for increased therapeutic or prophylactic measures in immunocompromised patients, including patients receiving cancer chemotherapy, and patients with cystic fibrosis, or rheumatoid arthritis.